Zimberelimab (AB122)

DRUG2 trials

Sponsors

Weill Medical College of Cornell University, MedSIR

Conditions

PDL-1 PositiveRectal CancerTriple Negative Breast Cancer

Phase 2

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

RecruitingNCT05024097

Weill Medical College of Cornell UniversityRectal Cancer

Start: 2022-03-31End: 2030-12-31Target: 43Updated: 2025-08-27

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Not yet recruitingNCT07134556

MedSIRPDL-1 Positive, Triple Negative Breast Cancer

Start: 2026-03-01End: 2028-12-28Target: 25Updated: 2026-01-23

Related Papers

Abstract PR005: Countering adenosine (ADO) in rectal cancer to improve RT responses to immune checkpoint blockade: a trial to test the safety and efficacy of PD1 (AB122) and ADO dual receptor (AB928) antagonists with chemotherapy after short-course RT

Cancer Immunology Research2025-02-23

Abstract P021: Countering adenosine (ADO) in rectal cancer to improve RT responses to immune checkpoint blockade: a trial to test the safety and efficacy of PD1 (AB122) and ADO dual receptor (AB928) antagonists with chemotherapy after short-course RT

Clinical Cancer Research2025-01-262 citations